Key result
Medical therapy improves LVEF by ~19 points in non-iron-overloaded β-thalassemia dilated cardiomyopathy.
Why the study?
Heart failure with reduced ejection fraction is rarely reported in β-thalassemia intermedia without iron deposition, and its etiology is unclear.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
b-thalassemia is a well-known single-gene disorder that causes microcytic anemia but has also been reported as a predisposing factor for heart failure (HF).
No takes yet. Share an insight, caveat, or question.
Higaki et al. (2023) conducted a case report in β-Thalassemia Intermedia and Dilated Cardiomyopathy (n=1). Cardioprotective medical therapy (sacubitril/valsartan, bisoprolol, spironolactone) was evaluated on Improvement in left ventricular ejection fraction (EF). A patient with transfusion-independent β-thalassemia intermedia developed dilated cardiomyopathy without iron deposition, with ejection fraction improving from 35% to 54% after 6 months of medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: